PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Christopher L. Hall *et al.*

Serial No.: 10/574,527

Filed: March 31, 2006

For: HUMAN PROSTATE CANCER CELL FACTOR(S) THAT INDUCE STEM CELL COMMITMENT AND OSTEOGENESIS

Group Art Unit: 1647

Examiner: Unknown

Atty. Dkt. No.: UMIC:050US

Confirmation No.: 6982

CERTIFICATE OF ELECTRONIC SUBMISSION

DATE OF SUBMISSION: December 5, 2006

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. § 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. § 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UMIC:050US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: December 5, 2006

Form PTO-1449 (modified)	Atty. Docket No. UMIC:050US	Serial No. 10/574,527
List of Patents and Publications for Applicant's	**Applicant** Christopher L. Hall *et al.*	
INFORMATION DISCLOSURE STATEMENT		
(Use several sheets if necessary)	**Filing Date:** March 31, 2006	**Group:** 1647

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Dai *et al.*, "Bone Morphogenetic Protein-6 Promotes Osteoblastic Prostate Cancer Bone Metastases through a Dual Mechanism," *Cancer Research*, 65:8274-8285, 2005.
	C2	Festuccia *et al.*, "Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma," *Oncology Res.*, 9(8):419-31, 1997.
	C3	Goltzman, "Mechanisms of the Development of Osteoblastic Metastases," *Cancer*, 80:1581-1587, 1997.
	C4	Haba, "Bone formation in mouse calvarium by the growth factor derived from prostatic cancer cell," *Mie Medical Journal*, 43:49-57, 1993 (abstract).
	C5	Kimura *et al.*, "Calcification in human osteoblasts cultured in medium conditioned by the prostatic cancer cell line PC-3 and prostatic acid phosphatase," *Urologia Internationalis*, 48(1):25-30, 1992.
	C6	LeRoy *et al.*, "Canine prostate induces new bone formation in mouse calvaria: A model of osteoinduction by prostate tissue," *Prostate*, 50(2):104-111, 2002.
	C7	Martinez *et al.*, "Prostate-derived soluble factors block osteoblast differentiation in culture." *J. Cell Biochem.*, 61(1):18-25, 1996.
	C8	Santibanez *et al.*, "Soluble factors produced by PC-3 prostate cells decrease collagen content and mineralisation rate in fetal rat osteoblasts in culture," *Brit. J. Cancer*, 74(3):418-22, 1996.

25659725.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.